We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

By LabMedica International staff writers
Posted on 16 Nov 2026

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. More...

Because mild cognitive impairment and dementia can develop over many years, longer-term risk estimates may provide more meaningful clinical context. Blood-based biomarkers could offer a less invasive way to support this type of risk assessment.

Researchers at Mayo Clinic evaluated phosphorylated tau 217 (p-tau217), a blood-based biomarker of Alzheimer’s disease, as part of a model to estimate future cognitive impairment risk in adults without symptoms. The approach combines p-tau217 levels with age, sex, and genetic risk to predict the likelihood of developing mild cognitive impairment or dementia. Higher p-tau217 concentrations and older age were associated with increased risk.

The study included 1,644 cognitively unimpaired participants from the Mayo Clinic Study of Aging and 534 from the Alzheimer’s Disease Neuroimaging Initiative. Participants were aged 60 to 90 and underwent blood p-tau217 testing, genetic assessment, and repeated cognitive evaluations. Researchers used Mayo Clinic data to develop five- and 10-year risk estimates, then confirmed the association between elevated p-tau217 levels and cognitive decline in the independent cohort.

For example, a 75-year-old woman without the APOE ε4 genetic risk variant had an estimated five-year risk of mild cognitive impairment of 5% with low p-tau217 levels, increasing to 16% with higher levels. Her estimated 10-year risk rose from 12% to 35%. At the same elevated p-tau217 level, five-year risk estimates also varied substantially by age, ranging from 6% at age 65 to 37% at age 85.

Published in JAMA Neurology on November 16, 2026, the findings build on earlier Mayo Clinic research using amyloid positron emission tomography (PET) imaging to predict cognitive impairment. Although the blood-based approach could support more individualized risk assessment, researchers emphasized the need for validation in more diverse populations and with other p-tau217 assays. Alzheimer’s biomarker testing is not currently recommended for individuals without cognitive symptoms.

“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” said Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.

“Absolute risk gives the biomarker result clinical context. If preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment,” said Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist and senior author of the study.

Related Links
Mayo Clinic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.